4 terminated, 3 active not recruiting, 3 completed, 1 not yet recruiting. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Terminated 4, Active not recruiting 3, Completed 3, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Metastatic Melanoma: new trials by email Literature Review of Metastatic Melanoma trials Research Report on Metastatic Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 3 | Active not recruiting | NRG Oncology | 274 | 2024-12-12 | 2026-09-14 |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period - Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Recruiting | Iovance Biotherapeutics, Inc. | 670 | 2023-03-30 | 2026-09-24 |
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) IO102-IO103, Pembrolizumab - Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Active not recruiting | IO Biotech | 407 | 2022-05-17 | 2025-08-28 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma | Phase 3 | Terminated | NRG Oncology | 19 | 2021-08-05 | 2026-05-20 |
| CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma CMP-001, Nivolumab - Melanoma, Advanced Melanoma | Phase 2 / Phase 3 | Terminated | Regeneron Pharmaceuticals | 20 | 2021-02-24 | 2026-06-15 |
| A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma Ipilimumab, Tilsotolimod with Ipilimumab - Metastatic Melanoma | Phase 3 | Terminated | Idera Pharmaceuticals, Inc. | 481 | 2018-05-30 | 2022-11-08 |
| A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W - Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 256 | 2018-02-02 | 2024-09-19 |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 267 | 2015-09-08 | 2026-11-18 |
| Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma Translational research, Cyclophosphamide, Fludarabine - Metastatic Melanoma | Phase 3 | Completed | The Netherlands Cancer Institute | 168 | 2014-09-23 | 2025-03-10 |
| Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit Masitinib, Dacarbazine - Metastatic Melanoma | Phase 3 | Terminated | AB Science | 134 | 2011-01-01 | 2020-11-05 |
| A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ) - Metastatic Melanoma | Phase 3 | Completed | Vical | 390 | 2006-10-01 | 2013-09-13 |
Melanoma (12) · Neoplasm Metastasis (4) · Skin Neoplasms (3) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Lung Neoplasms (2) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Gastrointestinal Neoplasms (1) · Small Cell Lung Carcinoma (1)
Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms by Site (12) · Neoplasms, Germ Cell and Embryonal (12) · Neoplasms, Nerve Tissue (12) · Neuroectodermal Tumors (12) · Neuroendocrine Tumors (12) · Nevi and Melanomas (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Skin Neoplasms (9) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Adenocarcinoma (2)
Dacarbazine (3) · Ipilimumab (3) · Nivolumab (3) · Magnetic Resonance Spectroscopy (2) · Radiosurgery (2) · Specimen Handling (2) · pembrolizumab (2) · Allovectin-7 (1) · Blood Specimen Collection (1) · CTLA-4 Antigen (1) · Cyclophosphamide (1) · Drug Therapy (1) · Interleukin-2 (1) · Memantine (1) · Temozolomide (1)
NRG Oncology (2) · AB Science (1) · IO Biotech (1) · Idera Pharmaceuticals, Inc. (1) · Iovance Biotherapeutics, Inc. (1) · National Cancer Institute (NCI) (1) · Regeneron Pharmaceuticals (1) · Scancell Ltd (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · The Netherlands Cancer Institute (1) · Vical (1)
United States (10) · Canada (5) · France (5) · Germany (5) · Italy (5) · Netherlands (5) · Spain (5) · United Kingdom (4) · Australia (3) · Belgium (3) · Czechia (3) · Israel (3) · Denmark (2) · Hong Kong (2) · Poland (2)
Inge Marie Svane, MD, Prof (1) · Jun Guo (1) · Linda Strause, PhD (1) · Michael B Atkins (1) · Rupesh R Kotecha (1) · Vinai Gondi (1)
PMID 29784747, PMID 36166727, PMID 36477031, PMID 40048691, PMID 40474841, PMID 40541863, PMID 41481311
U10CA180868 (2), U10CA180820 (1)